Profile data is unavailable for this security.
About the company
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
- Revenue in USD (TTM)172.96m
- Net income in USD83.97m
- Incorporated1995
- Employees45.00
- LocationSIGA Technologies Inc31 East 62Nd StreetNEW YORK 10065United StatesUSA
- Phone+1 (212) 672-9100
- Fax+1 (212) 697-3130
- Websitehttps://www.siga.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revance Therapeutics Inc | 247.00m | -180.81m | 359.42m | 597.00 | -- | -- | -- | 1.46 | -1.91 | -1.95 | 2.55 | -1.55 | 0.497 | 1.03 | 6.71 | 413,740.40 | -36.38 | -55.55 | -43.47 | -63.20 | 72.61 | -- | -73.20 | -304.96 | 3.05 | -15.40 | 1.58 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
Biostem Technologies Inc | 131.44m | 7.87m | 402.62m | 67.00 | 73.88 | 22.23 | 49.81 | 3.06 | 0.3346 | 0.3346 | 7.31 | 1.11 | 2.80 | 7.41 | 3.35 | -- | 16.78 | -- | 107.11 | -- | 94.73 | -- | 5.98 | -- | 1.20 | 15.52 | 0.2012 | -- | -- | -- | -- | -- | -- | -- |
Rigel Pharmaceuticals Inc | 157.47m | 3.88m | 438.99m | 147.00 | 115.15 | -- | 75.71 | 2.79 | 0.2167 | 0.2167 | 8.98 | -0.831 | 1.24 | 3.06 | 5.82 | 1,071,252.00 | 3.05 | -28.82 | 5.10 | -47.26 | 89.43 | 97.88 | 2.46 | -35.76 | 1.87 | 1.69 | 1.32 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
Theravance Biopharma Inc | 62.02m | -45.65m | 444.21m | 99.00 | -- | 2.29 | -- | 7.16 | -0.924 | -0.924 | 1.25 | 3.96 | 0.1534 | -- | 4.12 | 626,434.30 | -11.29 | -40.51 | -12.00 | -48.50 | -- | -- | -73.61 | -305.27 | -- | -- | 0.1305 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Aquestive Therapeutics Inc | 58.90m | -35.19m | 462.27m | 135.00 | -- | -- | -- | 7.85 | -0.4514 | -0.4514 | 0.7297 | -0.4982 | 0.6954 | 2.56 | 6.46 | 436,296.30 | -41.55 | -76.63 | -54.06 | -123.85 | 69.39 | 64.24 | -59.75 | -102.95 | 5.91 | -2.72 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
Zevra Therapeutics Inc | 23.99m | -65.75m | 471.46m | 65.00 | -- | 11.58 | -- | 19.66 | -1.67 | -1.67 | 0.6106 | 0.7734 | 0.1919 | -- | 2.09 | 369,015.40 | -52.61 | -32.11 | -65.34 | -39.89 | 71.78 | -- | -274.10 | -128.42 | -- | -112.94 | 0.6423 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
Amylyx Pharmaceuticals Inc | 196.49m | -259.47m | 478.62m | 384.00 | -- | 2.46 | -- | 2.44 | -3.82 | -3.82 | 2.87 | 2.86 | 0.5479 | 2.56 | 12.64 | 511,679.70 | -72.35 | -- | -84.00 | -- | 78.88 | -- | -132.05 | -- | 4.55 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
Xeris Biopharma Holdings Inc | 181.41m | -59.56m | 488.72m | 377.00 | -- | -- | -- | 2.69 | -0.4215 | -0.4215 | 1.28 | -0.1295 | 0.5493 | 0.7428 | 4.99 | 481,201.60 | -18.04 | -43.60 | -23.57 | -56.57 | 83.72 | 78.23 | -32.83 | -143.08 | 1.69 | -1.59 | 1.09 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
Esperion Therapeutics Inc | 295.45m | -86.77m | 494.49m | 240.00 | -- | -- | -- | 1.67 | -0.6585 | -0.6585 | 1.72 | -1.89 | 1.10 | 0.8275 | 5.35 | 1,231,046.00 | -32.41 | -69.45 | -74.85 | -101.81 | 81.58 | -- | -29.37 | -147.44 | 1.37 | 0.3253 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
SNDL Inc | 654.42m | -79.32m | 528.35m | 2.52k | -- | 0.6087 | -- | 0.8073 | -0.3027 | -0.3027 | 2.49 | 3.27 | 0.6062 | 4.98 | 36.38 | 260,104.70 | -7.61 | -24.44 | -8.22 | -27.94 | 25.69 | 22.49 | -12.55 | -62.17 | 4.16 | -- | 0.114 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
SIGA Technologies Inc | 172.96m | 83.97m | 538.12m | 45.00 | 6.49 | 3.21 | 6.37 | 3.11 | 1.16 | 1.16 | 2.41 | 2.35 | 1.02 | 0.5866 | 23.09 | 3,843,484.00 | 49.52 | 22.34 | 56.21 | 27.56 | 82.00 | 88.65 | 48.55 | 41.14 | 5.65 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
Elite Pharmaceuticals Inc | 66.45m | 19.58m | 577.94m | 64.00 | 28.28 | 9.92 | 27.44 | 8.70 | 0.0191 | 0.0191 | 0.064 | 0.0545 | 0.9892 | 2.91 | 4.98 | 1,038,252.00 | 29.15 | 19.07 | 36.18 | 24.29 | 45.27 | 46.63 | 29.47 | 20.77 | 2.09 | 1.44 | 0.1389 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
ASP Isotopes Inc | 2.30m | -27.05m | 588.52m | 76.00 | -- | 39.15 | -- | 256.36 | -0.628 | -0.628 | 0.0549 | 0.2112 | 0.068 | -- | -- | 30,206.32 | -71.81 | -- | -89.44 | -- | 36.54 | -- | -1,055.85 | -- | -- | -8.11 | 0.6748 | -- | -- | -- | -229.34 | -- | -- | -- |
Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
Emergent Biosolutions Inc | 1.13bn | -208.80m | 648.58m | 1.60k | -- | 1.27 | -- | 0.5763 | -4.10 | -4.10 | 21.19 | 9.40 | 0.6678 | 2.21 | 6.66 | 703,437.50 | -12.39 | -2.94 | -16.86 | -3.66 | 33.51 | 53.24 | -18.55 | -5.95 | 1.47 | -1.19 | 0.5658 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 30 Jun 2024 | 3.11m | 4.36% |
First Wilshire Securities Management, Inc.as of 30 Jun 2024 | 2.64m | 3.69% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 2.33m | 3.26% |
AltraVue Capital LLCas of 30 Jun 2024 | 2.18m | 3.05% |
Dimensional Fund Advisors LPas of 30 Sep 2024 | 1.81m | 2.54% |
Van Lanschot Kempen Investment Management NVas of 30 Jun 2024 | 1.72m | 2.41% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.13m | 1.58% |
D. E. Shaw & Co. LPas of 30 Jun 2024 | 1.07m | 1.51% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.05m | 1.47% |
Federated MDTA LLCas of 30 Jun 2024 | 1.01m | 1.42% |